China’s National Medical Products Administration has greenlit two Sanofi-licensed innovative therapies: Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy (oHCM) and Redemplo (plozasiran) for reducing triglyceride levels in adults with familial chylomicronaemia syndrome (FCS).

 

“We are pleased to bring Myqorzo and Redemplo to patients in Greater China. Both medicines represent important advances in treatment options and address unmet medical needs among people living with complex conditions,” said Olivier Charmeil, Executive Vice President, General Medicines, Sanofi. “The latest approvals underscore Sanofi’s long-term commitment to bringing innovative medicines to Chinese patients.”

 

Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM, a condition where the heart muscle thickens abnormally. It is the most common monogenic inherited cardiovascular disorder. The approval follows positive results from the pivotal SEQUOIA-HCM phase 3 trial (NCT05186818) in symptomatic patients.

 

Redemplo, a small-interfering RNA (siRNA) therapy, targets apolipoprotein C-III to reduce dangerously high triglyceride levels in patients with FCS. The rare condition can trigger life-threatening pancreatitis, chronic abdominal pain, diabetes, liver disease, and cognitive issues. Approval was supported by results from the PALISADE phase 3 trial (NCT05089084) in patients with genetically confirmed or clinically diagnosed FCS.

 

With these approvals, Sanofi strengthens its presence in China’s rare and complex disease landscape, offering patients groundbreaking options where few existed before.